Jupiter Asset Management’s Allogene Therapeutics ALLO Stock Holding History

Jupiter Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-17,868	Closed	-$204K	–	526
2022 Q2	$204K	Hold	17,868	–	–	﹤0.01%	553
2022 Q1	$163K	Buy	+17,868	New	+$186K	﹤0.01%	503

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jupiter Asset Management's ALLO Position: Q3 2022 in Review

Jupiter Asset Management sold out of Allogene Therapeutics (ALLO) in Q3 2022, closing a stake of 17,868 shares — an estimated $204K sold.

Jupiter Asset Management first reported a position in ALLO in Q1 2022 and held it in 2 quarters. The position peaked at $204K in Q2 2022. 192 funds tracked by Wall St. Rank hold ALLO as of Q3 2022.

Jupiter Asset Management reported no remaining Allogene Therapeutics position as of Q3 2022 after selling out during the quarter.
Jupiter Asset Management sold 17,868 Allogene Therapeutics shares in Q3 2022, an estimated $204K.
Jupiter Asset Management first reported a position in Allogene Therapeutics in Q1 2022 and held it in 2 quarters.
Jupiter Asset Management's Allogene Therapeutics position peaked at $204K in Q2 2022.
192 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2022.

Based on Jupiter Asset Management's 13F filing for Q3 2022, filed 10 Nov 2022.